Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
(Date:4/24/2014)... thought to be boring and irrelevant, could offer an ... , Researcher Dr Milena Furtado, and her team from ... found the heart cell fibroblast is a close relative ... beating heart. , In research published today in ... fibroblasts are unique cells due to their genetic program, ...
(Date:4/24/2014)... of researchers was the first in the world to ... tumour of the jaw. , Ameloblastoma is an odontogenic ... Ameloblastoma is most often found in the posterior of ... resulting in tissue deficiencies in the jaws as well ... could reduce the need for surgery and the recurrence ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... which comes from the foxglove plant, is normally used to ... the heart and treat heart diseases. The chemical nature of ... University of Wisconsin-Madison to make the drug fight against cancer//., ... works by changing the sugars attached to the drug. By ...
... According to a latest study researchers say health professionals ... manage the risks associated with over the counter drugs. ... one of the most common condition that people choose ... of the other commonly treated ailments include heartburn, migraine, ...
... stutent multi-kinase inhibitors against cancer is undergoing phase 3 ... this years ASCO (American Society of Clinical Oncology) conference. ... mechanism of action – known as Multi-kinase inhibitors. These ... and are found to be very effective. This two ...
... two different types of low fat, low cholesterol diets researchers ... diet consisting of lean meats and other low fat foods ... percent. However, those who consumed a diet rich in plant-based ... as well, lowering their LDL levels by about 9.4 percent. ...
... Researchers say Kelp seaweed may be the next food ... findings from an animal study conducted at the University ... the seaweed effectively reduced levels of estradiol, // a ... rats. The rats also experienced a lengthening of their ...
... say an indirect CT venography ( CTV ) could identify ... break free, travel to the lung, and block an artery ... arteries are not visible in a commonly used lung scan, ... presence of these blood clots in the lung. ...
Cached Medicine News:
... for use with GIA DST ... with Titanium Staples)., ,The ... and the SGIA™ Knifeless Stapler ... pediatric and thoracic surgical procedures ...
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... Device for use with VALTRAC™ ... Ring)., ,The Purstring™ Device ... and esophageal surgery for the ... and is intended for use ...
... to create an automatic purse-string with ... 45 disposable instrument has application in ... surgery for temporary and permanent purse-string ... disposable instrument has application in intestinal, ...
Medicine Products: